Drug Profile
Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals
Alternative Names: BEAT-HIV programme; dMAB ipilimumab; dMAb nivolumab; dMAb pembrolizumab; dMAB tremelimumab; dMAb™Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Developer AstraZeneca; Inovio Pharmaceuticals; Wistar Institute
- Class Anti-infectives; Antineoplastics; Antivirals; Bispecific antibodies; Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Chikungunya virus infections; Ebola virus infections; HIV infections; Influenza virus infections; Lyme disease; Pneumonia; Prostate cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Parenteral)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (Parenteral)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Lyme-disease in USA (Parenteral)